Rare lung disease encompasses a broad range of conditions. Today only a few rare lung diseases have approved treatments.
Kiox was founded to provide better treatments for patients with rare lung disease with no approved treatments and / or a large unmet need.
Kiox uses the inhaled route to maximise the efficacy and limit side-effects.
The Kiox team have solid experience in the development of drugs for respiratory diseases. The team have worked on projects spanning from ultra-rare to ultra-common lung diseases.
Kiox is supported by the Innovation Fund Denmark and a group of 9 private investors.
We collaborate with Iconovo, Løwenstein IP Management and AERA IP.